September 13, 2018

FACIT invests in three top Ontario entrepreneur-teams from near record pool of applicants

Prospects Oncology Fund seeds developing pipeline of Ontario-based biotech innovations

TORONTO, ON (September 13, 2018) – With an expanding portfolio of breakthrough innovations, FACIT is committed to supporting Ontario entrepreneurs through the latest round of its Prospects Oncology Fund. FACIT has selected three novel cancer therapeutic discoveries to receive early-stage capital – biotechnology start-up Talon Pharmaceuticals (“Talon”), the Drug Discovery team at the Ontario Institute for Cancer Research (“OICR”) and CCRM. The Prospects Fund provides entrepreneurial scientists with the capital resources necessary to achieve critical proof-of-principle studies for their cutting-edge breakthroughs aiming to benefit future patients.

Continue reading – FACIT invests in three top Ontario entrepreneur-teams from near record pool of applicants

September 4, 2018

Meet our students – 2018

Meet Dike Aduluso-Nwaobasi, Sarah Donald and Benson Wan. Find out how summer co-op positions affected their career and educational journeys.

August 22, 2018

Meet the researchers: Ratheesh Subramaniam

Ratheesh Subramaniam talks about his work in OICR’s Drug Discovery team and how it could help doctors make a difference in treating cancer patients.

July 31, 2018

Can an open drug discovery model find a solution for rare brain cancers in children?

Dr. Aled Edwards

Dr. Aled Edwards

OICR-funded drug discovery project’s unique ‘open science’ business model is accelerating the search for a solution to lethal pediatric brain cancers

Diffuse intrinsic pontine glioma (DIPG) is a lethal and inoperable brain cancer with a median survival of less than a year from diagnosis. Finding solutions to this disease is challenging due to its rarity, scientific complexity and its presentation in pediatric populations. An OICR-funded team of researchers, led by Dr. Aled Edwards from M4K Pharma, have developed new potential drug candidates for DIPG that they will test in animal models in the coming months. They’ve reached this milestone ahead of schedule, with fewer resources required than anticipated, by using an ‘open drug discovery’ approach – sharing their methods and data with the greater research community to streamline the drug discovery process.

Continue reading – Can an open drug discovery model find a solution for rare brain cancers in children?

December 4, 2017

OICR launches groundbreaking Cancer Therapeutics Innovation Pipeline to drive cutting-edge therapies to the clinic

Ten new projects were selected in the pipeline’s inaugural funding round, highlighting Ontario’s strengths in collaboration and drug discovery.

Toronto (December 4, 2017) – The Ontario Institute for Cancer Research (OICR) today announced the Cancer Therapeutics Innovation Pipeline (CTIP) initiative and the first 10 projects selected in CTIP’s inaugural round of funding. CTIP aims to support the local translation of Ontario discoveries into therapies with the potential for improving the lives of cancer patients. The funding will create a new pipeline of promising drugs in development, and attract the partnerships and investment to the province necessary for further clinical development and testing.

“Ontario congratulates OICR on this innovative approach to driving the development of new cancer therapies,” says Reza Moridi, Ontario’s Minister of Research, Innovation and Science. “The Cancer Therapeutics Innovation Pipeline will help ensure that promising discoveries get the support they need to move from lab bench to commercialization, and get to patients faster.”

Continue reading – OICR launches groundbreaking Cancer Therapeutics Innovation Pipeline to drive cutting-edge therapies to the clinic

March 22, 2017

FACIT Announces Investment in Propellon Therapeutics

Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development

TORONTO, March 22, 2017 /CNW/ – FACIT announced a seed stage investment in Propellon Therapeutics (the “Company” or “Propellon”), a start-up created by FACIT focused on developing a portfolio of WDR5-targeted anti-cancer therapeutics. FACIT’s investment, combined with non-dilutive capital, achieves a targeted $3.0M financing for the lead program. The seed funding enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.

Continue reading – FACIT Announces Investment in Propellon Therapeutics

February 10, 2017

How chemical probes can boost cancer research

Dr. David Uehling in the Lab.

Guest post by David Uehling, PhD, Ontario Institute for Cancer Research, on behalf of the Chemistry In Cancer Research Working Group, part of the American Association for Cancer Research (AACR).

The quest for a new cancer drug often begins when a protein target is implicated as an important driver in tumourigenesis. For cancer researchers, small molecules that block or stimulate such proteins can be valuable tools in research. Not only do they help us understand the role that the protein plays in cancer biology, but they also enable researchers to demonstrate which tumours are sensitive toward inhibition or stimulation with that protein target of interest, providing early clues as for patient selection and biomarker identification. Moreover, the knowledge that a small molecule can bind to such a protein builds confidence that this target is indeed “druggable,” which can provide a powerful stimulus to initiate a sustained effort to find medicines for that target.

Continue reading – How chemical probes can boost cancer research

December 6, 2016

Congratulations to Ahmed Aman on another successful Movember fundraiser

Dr. Ahmed Aman poses for a photo in front of a window

Dr. Ahmed Aman, Principal Research Scientist and Group Leader, Analytical Chemistry and ADME in OICR’s Drug Discovery Program, recently demonstrated that his commitment to cancer research goes beyond his work in the lab. For the sixth straight year Aman participated in Movember by growing a moustache to raised funds and awareness for men’s health issues, including prostate cancer. This year Aman exceeded his fundraising goal of $500 by collecting $770 in donations and has now raised $3,445 since beginning in 2011.

More information about Movember can be found here: https://ca.movember.com/

September 19, 2016

Open resource: How we’re making our research resources more accessible to the community

OICR Researcher in the lab

Dr. Rebecca Tamarchak discusses the launch of OICR’s new Collaborative Research Resources Directory, how it works, and plans for its development in the future.

Over the past decade, OICR has established state-of-the-art Technology Programs in molecular pathology and diagnostic development, genomics, informatics, medicinal chemistry and imaging, which are translating promising cancer discoveries into products, services and policies that improve cancer prevention and care for patients.

Continue reading – Open resource: How we’re making our research resources more accessible to the community

August 18, 2016

Registration now open for the Mark Ernsting Drug Discovery Memorial Lecture

Mark Ernsting Lecture

Join us for the inaugural Mark Ernsting Drug Discovery Memorial Lecture. The Lecture is named in honour of Dr. Mark Ernsting, who was a Senior Biomedical Engineer in the Drug Discovery Program at OICR. Dr. Ernsting passed away in December 2015. He was a brilliant and passionate scientist and a great colleague and friend. Dr. Ernsting endeavoured to improve the lives of cancer patients by developing nanomedicines designed to deliver safer and more effective drugs.

Title of talk: Chemistry towards novel mechanism-of-action (nMoA) compounds in therapeutics discovery

Speaker: Stuart L. Schreiber, PhD
Morris Loeb Professor
Director, Center for the Science of Therapeutics
Harvard University
Broad Institute of MIT and Harvard

When: September 22, 2016, 3-5 p.m.

Where: The Great Hall, Hart House, University of Toronto, 7 Hart House Circle, Toronto, Ontario M5S 3H3

More information and free registration:
https://www.eventbrite.ca/e/mark-ernsting-drug-discovery-memorial-lecture-given-by-dr-stuart-schreiber-tickets-27005851228

July 26, 2016

OICR is making its technology infrastructure, expertise and resources more available to the Ontario cancer community

Photo of OICR researcher using equipment

Technology platforms are often one of the biggest enablers of high-impact research. Since it was established in 2005, OICR has invested in developing technology infrastructure, expertise and resources in diagnostic development, genomics, imaging, informatics and medicinal chemistry. These clusters consist of research and technical experts and state-of-the-art equipment.

Continue reading – OICR is making its technology infrastructure, expertise and resources more available to the Ontario cancer community

July 18, 2016

Save the date: Mark Ernsting Drug Discovery Memorial Lecture on September 22, 2016

Dr. Mark Ernsting

This fall, members of the cancer research community will gather for the inaugural Mark Ernsting Drug Discovery Memorial Lecture. The Lecture is named in honour of Dr. Mark Ernsting, who was a Senior Biomedical Engineer in the Drug Discovery Program at OICR. Dr. Ernsting passed away in December 2015. He was a brilliant and passionate scientist and a great colleague and friend. Dr. Ernsting endeavoured to improve the lives of cancer patients by developing nanomedicines designed to deliver more effective drugs that minimize toxicity.

Date: September 22, 2016
Time: 3-5 p.m.
Location: The Great Hall, Hart House, University of Toronto
Keynote speaker: Dr. Stuart Schreiber, Broad Institute of Harvard and MIT

Next Page »